Angel News

Angel News

Back to Homepage

27th November 2018

OMass Therapeutics announces £14 M Series A financing

OMass Therapeutics, a biopharmaceutical company using structural mass spectrometry to discover novel medicines, has announced completion of a £14 million Series A financing. New investor Syncona Ltd led the round, alongside Oxford Sciences Innovation. The financing supports development of a pipeline of drug development programmes.


Register now to read full story

In order to read the full story we need you to register with us, please click the link below:

Register Now

Add a comment:




Enter the characters in the image shown:

Back to Homepage